Project Grant R01CA295626
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $727K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
- This Project Grant award of $662,938, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research at Northwestern University to investigate the role of gain-of-function mutant p53 proteins in acute myeloid leukemia (AML). The central objective is to determine how these p53 mutations promote leukemia-initiating cell self-renewal, chromatin accessibility, and 3D chromatin structure, which may contribute to therapy resistance in AML....
- This $458,698 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of Michigan to identify cellular and molecular mechanisms underlying therapy resistance and disease relapse in acute myeloid leukemia (AML). The project aims to characterize genes and pathways that confer growth advantages to leukemic stem cells, enabling them to persist and regenerate disease after initial clinical remission. This 5-year...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to Case Western Reserve University to conduct research aimed at understanding the fundamental biological mechanisms of acute myeloid leukemia (AML) and developing new therapeutic approaches. The $491,357 award supports investigations into using proteasome inhibitors and an mTORC1 activator molecule to induce metabolic stress and resensitize AML cells to treatment, particularly...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports fundamental research aimed at understanding the biological mechanisms underlying acute myeloid leukemia (AML) development and progression. The $487,973 award to The Leland Stanford Junior University will fund a 5-year project investigating the role of pre-leukemic hematopoietic stem cells (pHSCs) in AML pathogenesis. The research will explore the clonal evolution, kinetics, and cell...
- This $495,715 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sloan-Kettering Institute for Cancer Research to decipher the pathogenesis and therapeutic vulnerabilities of acute myeloid leukemia (AML) driven by germline RUNX1 mutations. The project aims to develop faithful preclinical models, including genetically engineered mouse models and patient-derived xenografts, to study the genetic events and disease progression from...
- This five-year $360,281 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Biology Research program (CFDA 93.396). The grantee, Washington University, will conduct studies to define the contribution of altered epigenetic patterns and genome organization to the pathogenesis of acute myeloid leukemia (AML). Researchers will perform comprehensive epigenetic analysis of DNA methylation and three-dimensional...
- The National Cancer Institute (CFDA 93.396 Cancer Biology Research) awarded a $477,218 Project Grant to Northwestern University to study the persistence of leukemia stem cells during tyrosine kinase inhibitor treatment in chronic myeloid leukemia (CML). The research aims to understand the mechanisms behind the emergence of quiescent and proliferative leukemia stem cell subsets, and their interaction with ABT cells, which influences the duration of therapy-free remission in CML patients. The...
- This Project Grant award of $502,516 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Case Western Reserve University focused on developing a small-molecule degrader called SISU-102 to target leukemic stem cells (LSCs) in acute myeloid leukemia (AML). The key objectives are to further investigate the impacts of these HSF1 degraders on LSC self-renewal, identify sensitive and resistant AML subtypes, and explore the underlying mechanisms. This...
- This federal Project Grant award of $676,550 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to understand the impact of socioeconomic status (SES) and adversity on hematopoietic cell transplant (HCT) outcomes in pediatric patients with high-risk hematological malignancies. The primary goals are to: 1) quantify the association between donor and recipient SES with pediatric HCT outcomes, and 2) evaluate how donor and recipient SES...
- This $160,500 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of mouse models to investigate the role of Caspase-2 in nucleophosmin (NPM1)-mutated acute myeloid leukemia (AML). The project aims to determine the impact of Caspase-2 loss on the self-renewal and myeloproliferative disease progression of NPM1-mutated AML cells. The research is being conducted by the Baylor College of Medicine, a leading private,...